Glycomimetics Inc financial data

Symbol
GLYC on Nasdaq
Industry
Pharmaceutical Preparations
Location
9708 Medical Center Drive, Rockville, MD
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 668 % -14.1%
Debt-to-equity 17.3 % +18.2%
Return On Equity -117 % -62.5%
Return On Assets -99.6 % -58.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.5M shares +0.26%
Common Stock, Shares, Outstanding 64.5M shares +0.27%
Entity Public Float 109M USD +254%
Common Stock, Value, Issued 64.5K USD +0.27%
Weighted Average Number of Shares Outstanding, Basic 64.5M shares +0.32%
Weighted Average Number of Shares Outstanding, Diluted 64.5M shares +0.32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.9M USD +12.7%
General and Administrative Expense 18M USD -5.07%
Operating Income (Loss) -40.9M USD -4.12%
Net Income (Loss) Attributable to Parent -39.1M USD -4.62%
Earnings Per Share, Basic -0.61 USD/shares +7.58%
Earnings Per Share, Diluted -0.61 USD/shares +7.58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.4M USD -61.4%
Assets, Current 23.9M USD -60.5%
Property, Plant and Equipment, Net 133K USD -53.8%
Operating Lease, Right-of-Use Asset 424K USD -64.1%
Assets 24.4M USD -60.5%
Accounts Payable, Current 951K USD +294%
Accrued Liabilities, Current 2.96M USD -46.3%
Liabilities, Current 4.36M USD -33.7%
Operating Lease, Liability, Noncurrent 66.8K USD
Liabilities 4.36M USD -38%
Retained Earnings (Accumulated Deficit) -477M USD -8.93%
Stockholders' Equity Attributable to Parent 20.1M USD -63.4%
Liabilities and Equity 24.4M USD -60.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD +9.46%
Net Cash Provided by (Used in) Financing Activities 28.7M USD
Net Cash Provided by (Used in) Investing Activities -7.44K USD -239%
Common Stock, Shares Authorized 150M shares +50%
Common Stock, Shares, Issued 64.5M shares +0.27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.5M USD -161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.5M USD -42.2%
Deferred Tax Assets, Valuation Allowance 161M USD +7.59%
Deferred Tax Assets, Gross 162M USD +7.48%
Operating Lease, Liability 449K USD -64.6%
Depreciation 124K USD -35.3%
Payments to Acquire Property, Plant, and Equipment 7.44K USD +239%
Lessee, Operating Lease, Liability, to be Paid 464K USD -66.1%
Property, Plant and Equipment, Gross 2.64M USD +0.54%
Operating Lease, Liability, Current 449K USD -45.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 67.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 67.4K USD -91.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15.2K USD -84.7%
Deferred Tax Assets, Operating Loss Carryforwards 88.7M USD +7.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 850K USD -24%
Additional Paid in Capital 497M USD +0.89%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 211K USD -39.8%
Share-based Payment Arrangement, Expense 4.2M USD +18.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%